125 related articles for article (PubMed ID: 25098985)
1. Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.
Logeswari J; Malathi N; Thamizhchelvan H; Sangeetha N; Nirmala SV
Indian J Dent Res; 2014; 25(3):305-10. PubMed ID: 25098985
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia.
D'souza B; Nayak R; Kotrashetti VS
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):132-139. PubMed ID: 27153448
[TBL] [Abstract][Full Text] [Related]
3. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
Kawaguchi H; El-Naggar AK; Papadimitrakopoulou V; Ren H; Fan YH; Feng L; Lee JJ; Kim E; Hong WK; Lippman SM; Mao L
J Clin Oncol; 2008 Jan; 26(3):354-60. PubMed ID: 18202409
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin expression in oral leukoplakia: tumorigenic role.
de Vicente JC; Rodrigo JP; Rodriguez-Santamarta T; Lequerica-Fernández P; Allonca E; García-Pedrero JM
Oral Oncol; 2013 Jun; 49(6):598-603. PubMed ID: 23473850
[TBL] [Abstract][Full Text] [Related]
5. Podoplanin expression in tumor-free resection margins of oral squamous cell carcinomas: an immunohistochemical and fractal analysis study.
Margaritescu C; Raica M; Pirici D; Simionescu C; Mogoanta L; Stinga AC; Stinga AS; Ribatti D
Histol Histopathol; 2010 Jun; 25(6):701-11. PubMed ID: 20376776
[TBL] [Abstract][Full Text] [Related]
6. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance.
dos Santos Almeida A; Oliveira DT; Pereira MC; Faustino SE; Nonogaki S; Carvalho AL; Kowalski LP
Anticancer Res; 2013 Sep; 33(9):3969-76. PubMed ID: 24023336
[TBL] [Abstract][Full Text] [Related]
7. Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis.
Parhar S; Kaur H; Vashist A; Verma S
Indian J Cancer; 2015; 52(4):617-22. PubMed ID: 26960495
[TBL] [Abstract][Full Text] [Related]
8. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity.
Inoue H; Miyazaki Y; Kikuchi K; Yoshida N; Ide F; Ohmori Y; Tomomura A; Sakashita H; Kusama K
Tumour Biol; 2012 Feb; 33(1):183-94. PubMed ID: 22081310
[TBL] [Abstract][Full Text] [Related]
9. [Podoplanin expression in oral squamous cell carcinoma and leukoplakia and its correlation with lymph vessels density].
Zhang G; Guo ZL; Gao Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Aug; 44(8):488-91. PubMed ID: 19961757
[TBL] [Abstract][Full Text] [Related]
10. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study.
Sudha VM; Hemavathy S
Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045
[TBL] [Abstract][Full Text] [Related]
11. Podoplanin expression in oral leukoplakia─a prospective study.
Grochau KJ; Safi AF; Drebber U; Grandoch A; Zöller JE; Kreppel M
J Craniomaxillofac Surg; 2019 Mar; 47(3):505-509. PubMed ID: 30638740
[TBL] [Abstract][Full Text] [Related]
12. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.
Mei Y; Zhang P; Zuo H; Clark D; Xia R; Li J; Liu Z; Mao L
Oncogene; 2014 Jul; 33(29):3839-50. PubMed ID: 23975429
[TBL] [Abstract][Full Text] [Related]
13. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications.
Kreppel M; Kreppel B; Drebber U; Wedemayer I; Rothamel D; Zöller JE; Scheer M
Oral Dis; 2012 Oct; 18(7):692-9. PubMed ID: 22471854
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-375 as a biomarker for malignant transformation in oral lesions.
Harrandah AM; Fitzpatrick SG; Smith MH; Wang D; Cohen DM; Chan EK
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Dec; 122(6):743-752.e1. PubMed ID: 27720656
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.
Funayama A; Cheng J; Maruyama S; Yamazaki M; Kobayashi T; Syafriadi M; Kundu S; Shingaki S; Saito C; Saku T
Pathobiology; 2011; 78(3):171-80. PubMed ID: 21613804
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
Patil A; Patil K; Tupsakhare S; Gabhane M; Sonune S; Kandalgaonkar S
Scientifica (Cairo); 2015; 2015():135298. PubMed ID: 26558136
[TBL] [Abstract][Full Text] [Related]
17. Podoplanin expressing cancer-associated fibroblasts in oral cancer.
Inoue H; Tsuchiya H; Miyazaki Y; Kikuchi K; Ide F; Sakashita H; Kusama K
Tumour Biol; 2014 Nov; 35(11):11345-52. PubMed ID: 25119595
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation.
Aiswarya A; Suresh R; Janardhanan M; Savithri V; Aravind T; Mathew L
J Oral Maxillofac Pathol; 2019; 23(1):159. PubMed ID: 31110440
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.
Seki S; Fujiwara M; Matsuura M; Fujita S; Ikeda H; Umeda M; Asahina I; Ikeda T
Pathol Oncol Res; 2014 Jul; 20(3):521-8. PubMed ID: 24281769
[TBL] [Abstract][Full Text] [Related]
20. [The relationship of Fas and Fas L protein expression in oral carcinogenesis].
Zeng X; Chen Q; Nie M
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Aug; 21(4):259-62. PubMed ID: 14513577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
